Abstract
Modeling and simulation are important tools that can be used to control, prevent and understand an epidemic spread. This paper introduces a symptomatic-asymptomatic-recoverer-death differential equation model (SARDDE). It presents the conditions of the asymptotical stability on the disease-free equilibrium of the SARDDE. It proposes the necessary conditions of disease spreading for the SARDDE. Based on the reported data of the first and the second COVID-19 epidemics in Beijing and simulations, it determines the parameters of the SARDDE, respectively. Numerical simulations of the SARDDE describe well the outcomes of current symptomatic and asymptomatic individuals, recovered symptomatic and asymptomatic individuals, and died individuals, respectively. The numerical simulations suggest that both symptomatic and asymptomatic individuals cause lesser asymptomatic spread than symptomatic spread; the blocking rates of about 90% and 97% to the symptomatic individuals cannot prevent the spread of the first and second COVID19 epidemics in Beijing, respectively. Virtual simulations suggest that the strict prevention and control strategies implemented by Beijing government are effective and necessary. The numerical simulations suggest also that using the data from the beginning to the days after about two weeks from the turning points can estimate approximately the following outcomes of the two COVID-19 academics, respectively. It is expected that the research can provide better understanding, explaining, and dominating for epidemic spreads, prevention and control measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding supported in the work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB/oversight body that provided approval or exemption for the research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Dear Editor, The main changes of the amended version are listed as follows: (1) Regulate some paragraph orders in Section 2. (2) Give the concrete representations of parameters ``alpha kappa'' (please see (21)-(26); (31-35). (3) Embed the content into the text. Best wishes! Lequan
Data Availability
All data cite in this article selected from the web ref. [13] (http://wjw.beijing.gov.cn/
